News
Eli Lilly had a lot riding on its two phase 3 trials of IL-13 inhibitor lebrikizumab in atopic dermatitis (AD) – and it now looks like it has ... and Regeneron's Dupixent (dupilumab) in AD.
Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
About Dupixent Dupixent (dupilumab) is available in Japan in a 300 mg dose as a pre-filled syringe or pre-filled pen and is now available for COPD. Dupixent is intended for injection under the ...
Eli Lilly had a lot riding on its two phase 3 trials of IL-13 inhibitor lebrikizumab in atopic dermatitis (AD) – and it now looks like it has ... and Regeneron's Dupixent (dupilumab) in AD.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback